Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study

被引:34
|
作者
Verhagen, Sandra N. [1 ]
Wassink, Annemarie M. J. [1 ]
van der Graaf, Yolanda [2 ]
Gorter, Petra M. [1 ]
Visseren, Frank L. J. [1 ]
机构
[1] Univ Med Ctr Utrecht UMC Utrecht, Dept Vasc Med, Utrecht, Netherlands
[2] UMC Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands
来源
关键词
Insulin resistance; Manifest arterial disease; Metabolic syndrome; HOMEOSTASIS MODEL ASSESSMENT; ABDOMINAL AORTIC-ANEURYSM; GLUCOSE CLAMP TECHNIQUE; CORONARY-HEART-DISEASE; METABOLIC SYNDROME; CEREBROVASCULAR-DISEASE; INCREASED RISK; SENSITIVITY; STIFFNESS; OBESITY;
D O I
10.1186/1475-2840-10-100
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Insulin resistance is accompanied by a cluster of metabolic changes, often referred to as metabolic syndrome. Metabolic syndrome is associated with an increased cardiovascular risk in patients with manifest arterial disease. We investigated whether insulin resistance is associated with an increased risk for cardiovascular events in patients with manifest arterial disease without known diabetes and whether this can be explained by the components of the metabolic syndrome or by inflammation. Methods: Prospective cohort study in 2611 patients with manifest arterial disease without known diabetes. Homeostasis model of insulin resistance (HOMA-IR) was used to quantify insulin resistance. The relation of HOMA-IR with cardiovascular events (vascular death, myocardial infarction or stroke) and all cause mortality was assessed with Cox regression analysis. In additional models adjustments were performed for the single components constituting the metabolic syndrome and for inflammation. Results: HOMA-IR increases with the number of metabolic syndrome components (mean HOMA-IR +/- SD in groups with 0, 1, 2, 3, 4 and 5 metabolic syndrome components: 1.4 +/- 0.7; 1.8 +/- 1.2; 2.4 +/- 1.5; 3.1 +/- 1.8; 4.0 +/- 2.6; and 5.6 +/- 3.6 respectively). High HOMA-IR was independently associated with an increased risk of cardiovascular events (tertile 2 vs. 1 HR 1.92; 95% CI 1.20-3.08) (tertile 3 vs. 1 HR 1.78; 95% CI 1.10-2.89) and with all cause mortality (tertile 2 vs. 1 HR 1.80; 95% CI 1.04-3.10) (tertile 3 vs. 1 HR 1.56; 95% CI 0.88-2.75). These relations were not influenced by the individual components of metabolic syndrome or by inflammation. Conclusions: In patients with manifest arterial disease without known diabetes, insulin resistance increases with the number of metabolic syndrome components, and elevated insulin resistance increases the risk of new cardiovascular events.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Insulin resistance increases the occurrence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
    Sandra N Verhagen
    Annemarie MJ Wassink
    Yolanda van der Graaf
    Petra M Gorter
    Frank LJ Visseren
    Cardiovascular Diabetology, 10
  • [2] Insulin resistance increases the incidence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
    Verhagen, S. N.
    Gorter, P. M.
    Van der Graaf, Y.
    Visseren, F. L. J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183 : 684 - 684
  • [3] Insulin resistance increases the incidence of new cardiovascular events in patients with manifest arterial disease without known diabetes. The SMART study
    Verhagen, S. N.
    Gorter, P. M.
    Van der Graaf, Y.
    Visseren, F. L. J.
    EUROPEAN HEART JOURNAL, 2011, 32 : 684 - 684
  • [4] Carotid stiffness and the risk of new vascular events in patients with manifest cardiovascular disease. The SMART study
    Dijk, JM
    Algra, A
    van der Graaf, Y
    Grobbee, DE
    Bots, ML
    EUROPEAN HEART JOURNAL, 2005, 26 (12) : 1213 - 1220
  • [5] Carotid stiffness and the risk of new vascular events in patients with manifest cardiovascular disease. The smart study
    Dijk, J. M.
    Algra, A.
    van der Graaf, Y.
    Grobbee, D. E.
    Bots, M. L.
    EUROPEAN JOURNAL OF EPIDEMIOLOGY, 2006, 21 : 19 - 19
  • [6] The impact of site and extent of clinically evident cardiovascular disease and atherosclerotic burden on new cardiovascular events in patients with Type 2 diabetes. The SMART study
    Gorter, P. M.
    Visseren, F. L. J.
    Algra, A.
    van der Graaf, Y.
    DIABETIC MEDICINE, 2007, 24 (12) : 1352 - 1360
  • [7] The impact of Type 2 diabetes and microalbuminuria on future cardiovascular events in patients with clinically manifest vascular disease from the Second Manifestations of ARTerial disease (SMART) study
    Soedamah-Muthu, S. S.
    Visseren, F. L. J.
    Algra, A.
    van der Graaf, Y.
    DIABETIC MEDICINE, 2008, 25 (01) : 51 - 57
  • [8] Alcohol consumption and risk of recurrent cardiovascular events and mortality in patients with clinically manifest vascular disease and diabetes mellitus: The Second Manifestations of ARTerial (SMART) disease study
    Beulens, J. W. J.
    Algra, A.
    Soedamah-Muthu, S. S.
    Visseren, F. L. J.
    Grobbee, D. E.
    van der Graaf, Y.
    ATHEROSCLEROSIS, 2010, 212 (01) : 281 - 286
  • [9] Asymptomatic carotid artery stenosis and the risk of new vascular events in patients with manifest arterial disease - The SMART study
    Goessens, Bertine M. B.
    Visseren, Frank L. J.
    Kappelle, L. Jaap
    Algra, Ale
    van der Graaf, Yolanda
    STROKE, 2007, 38 (05) : 1470 - 1475
  • [10] Hemoglobin and atherosclerosis in patients with manifest arterial disease - The SMART-study
    Dijk, J. M.
    Wangge, G.
    van der Graaf, Y.
    Bots, M. L.
    Grobbee, D. E.
    Algra, A.
    ATHEROSCLEROSIS, 2006, 188 (02) : 444 - 449